Onco-Innovations Initiates ADME Studies Supporting Development of ONC010

Calgary, Canada – July 16, 2026 – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) (“Onco“ or the “Company”) announces, further to its news release dated May 8, 2026, the initiation of key absorption, distribution, metabolism and excretion (“ADME”) studies for ONC010, the Company’s lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) inhibitor. The studies are designed to characterize ONC010’s pharmacokinetic and metabolic profile and support the continued IND-enabling development of the program.

The initial ADME work is focused on metabolism of the active pharmaceutical ingredient (API) in the ONC010 lead drug candidate. These data are intended to support the Company’s broader development strategy by informing manufacturing activities, formulation optimization, toxicology studies and future clinical translation. The studies are expected to contribute to the growing body of preclinical evidence supporting the continued advancement of ONC010 toward clinical evaluation.

“Initiating these ADME studies represents another important step in our systematic advancement of ONC010. A thorough understanding of how a therapeutic candidate is absorbed, distributed, metabolized and eliminated is fundamental to successful drug development,“ said Thomas O’Shaughnessy, Chief Executive Officer of Onco-Innovations.

The ADME studies form part of Onco-Innovations’ broader IND-enabling development program for ONC010, which also includes manufacturing, formulation, safety and regulatory activities intended to support future clinical evaluation.

“ADME studies play a critical role in evaluating the clinical potential of an investigational oncology therapy. The data generated through this program are expected to provide valuable information to support dose selection, safety assessment and overall development planning. These studies will further strengthen the scientific foundation of the ONC010 program as we continue progressing toward clinical translation,“ said Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations.

About ONC010

ONC010 is a novel nanoparticle-formulated inhibitor of Polynucleotide Kinase Phosphatase (PNKP), a key DNA damage repair enzyme. The program is being developed to exploit vulnerabilities in cancer cells dependent on DNA repair pathways and is intended to provide a differentiated therapeutic approach for patients with difficult-to-treat malignancies.

About Onco-Innovations Limited

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco’s mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The Company has secured an exclusive worldwide license to patented technology that targets solid tumours.

ON BEHALF OF ONCO-INNOVATIONS LIMITED,

“Thomas O’Shaughnessy”

Chief Executive Officer

For more information, please contact:

Thomas O’Shaughnessy

Chief Executive Officer

Tel: + 1 888 261 8055

investors@oncoinnovations.com

Forward-Looking Statements Caution. This news release contains forward-looking statements, including in relation to the Company’s research and development plans, business and plans generally, and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “potential”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. In particular, the Company may not be able to carry out its research and development plans for a variety of reasons, including, but not limited to, the failure to receive regulatory approvals, the failure to maintain contractual relations and the failure to obtain financing and retain key personnel. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.